Results 91 to 100 of about 92,649 (309)

Clinical progress note: Hepatitis A virus

Journal of Hospital Medicine, EarlyView.
Abstract Despite a decline in hepatitis A virus (HAV) incidence following vaccine introduction, HAV remains a public health concern in the United States. Recent multi‐state outbreaks have demonstrated that HAV can re‐emerge and highlight inequities in vaccine coverage or access, outbreak response, and in those with social or health risk factors ...
James M. McCluskey III, Robyn A. Bockrath, Ravi Jhaveri   +2 more
wiley   +1 more source

Research advances in replication-deficient viral vector vaccines

Frontiers in Veterinary Science
In recent years, replication-deficient viral vector vaccines have attracted much attention in the field of vaccine research and development due to their high safety and immunogenicity.
Junna Wang, Junna Wang, Jin Cui, Guoxin Li, Lingxue Yu, Lingxue Yu   +5 more
doaj   +1 more source

VLP (Virus-Like Particles) Vaccines - Current Knowledge and Future Directions [PDF]

Brazilian Archives of Biology and Technology
Viruses are acellular, potential pathogenic agents causing infections, ranging from acute to chronic. A wide range of conventional immunization methodologies have been employed to control viral diseases. But, their ability to mutate or remain inactive in
Prakash Meghana, Mangalam Achuthananda Iyer Jayasri, Krishnamurthy Suthindhiran   +2 more
doaj   +1 more source

Serological immunity against vaccine‐preventable diseases in children with inflammatory bowel disease at diagnosis

JPGN Reports, EarlyView.
Abstract Objectives Patients with inflammatory bowel disease (IBD) are at increased risk of vaccine‐preventable diseases. However, vaccination coverage in this population is often suboptimal. This retrospective study assessed the vaccination status and vaccine serology of children diagnosed with IBD in a high‐income country with broad vaccine access ...
Clara Noble, Renato Gualtieri, Klara Posfay‐Barbe, Nathalie Rock, Geraldine Blanchard‐Rohner   +4 more
wiley   +1 more source

Features of Effective T Cell-Inducing Vaccines against Chronic Viral Infections

Frontiers in Immunology, 2018
For many years, the focus of prophylactic vaccines was to elicit neutralizing antibodies, but it has become increasingly evident that T cell-mediated immunity plays a central role in controlling persistent viral infections such as with human ...
Eleni Panagioti, Eleni Panagioti, Paul Klenerman, Lian N. Lee, Sjoerd H. van der Burg, Ramon Arens   +5 more
doaj   +1 more source

Risk Factors For Multiple Sclerosis In Volyn Region (Ukraine) [PDF]

, 2016
The prevalence rate of multiple sclerosis (MS) in Volyn Region (101.0 per 100000) is the highest in Ukraine. To study MS risk factors in Volyn Region, special questionnaires were distributed among all MS patients residing in Volyn region.
Bobryk, N. (Nataliia), Sokolova, L. (Larysa)   +1 more
core   +2 more sources

Identification of Clinical Factors Associated With the Immunogenicity of Homologous ChAdOx1‐nCoV‐19 Vaccine in Hemodialysis Patients

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Hemodialysis (HD) patients are at higher risk of severe COVID‐19 and may exhibit suboptimal vaccine responses. This study evaluates the factors influencing vaccine‐induced immunity in HD patients following the second dose of the Vaxzevria. A total of 276 HD patients and 126 controls were included. Antibody responses were assessed using binding
Chia‐Wei Chang, Ping‐Hsun Wu, Li‐Yun Chang, Yu‐Ying Huang, Teng‐Hui Huang, Su‐Chu Lee, Yi‐wen Chiu, Shang‐Jyh Hwang, Tsun‐Yung Kuo, Mei‐Chuan Kuo   +9 more
wiley   +1 more source

A Stochastic Model to Assess the Epidemiological Impact of Vaccine Booster Doses on COVID-19 and Viral Hepatitis B Co-Dynamics with Real Data [PDF]

, 2023
Andrew Omame, Mujahid Abbas, Dumitru Bǎleanu   +2 more
openalex   +1 more source

Few and Far Between: How HIV May Be Evading Antibody Avidity [PDF]

, 2010
No ...
Bjorkman, Pamela J., Klein, Joshua S.
core   +3 more sources

Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy

Medicine Bulletin, EarlyView.
ABSTRACT Recently, immune checkpoint inhibitors (ICIs), particularly PD‐1/PD‐L1 and CTLA‐4 inhibitors, have revolutionized cancer treatment, significantly improving survival rates for various malignancies. However, ICI therapies targeting single checkpoints on T cells still face numerous challenges, such as low response rates and post‐treatment ...
Yangyang Li, Zizhen Kang, Yanyun Du
wiley   +1 more source